Claudio Bravo

Dr. Claudio Bravo

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 October 2022 in Frontiers in Cardiovascular Medicine
Verified
Journal Article
Open access
CBClaudio Bravo
Claudio Bravo
ANAndrew G. Navarro
Andrew G. Navarro
KDKaranpreet K. Dhaliwal
Karanpreet K. Dhaliwal
MKMaziar Khorsandi
Maziar Khorsandi
JKJeffrey E. Keenan
Jeffrey E. Keenan
CMClaudius Mahr
Claudius Mahr
Left ventricular assist device (LVAD) therapy is a lifesaving option for patients with medical therapy-refractory advanced heart failure. Depending on the definition, 5–44% of people supported with an LVAD develop right heart failure (RHF), which is associated with worse outcomes. The mechanisms related to RHF include patient, surgical, and hemodynamic factors. Despite significant progress in understanding the roles of these factors and improvements in surgical techniques and LVAD technology, this complication is still a substantial cause of morbidity and mortality among LVAD patients. Additionally, specific medical therapies for this complication still are lacking, leaving cardiac transplantation or supportive management as the only options for LVAD patients who develop RHF. While significant effort has been made to create algorithms aimed at stratifying risk for RHF in patients undergoing LVAD implantation, the predictive value of these algorithms has been limited, especially when attempts at external validation have been undertaken. Perhaps one of the reasons for poor performance in external validation is related to differing definitions of RHF in external cohorts. Additionally, most research in this field has focused on RHF occurring in the early phase (i.e., ≤1 month) post LVAD implantation. However, there is emerging recognition of late-onset RHF (i.e., > 1 month post-surgery) as a significant cause of morbidity and mortality. Late-onset RHF, which likely has a unique physiology and pathogenic mechanisms, remains poorly characterized. In this review of the literature, we will describe the unique right ventricular physiology and changes elicited by LVADs that might cause both early- and late-onset RHF. Finally, we will analyze the currently available treatments for RHF, including mechanical circulatory support options and medical therapies.

1 October 2018 in The American Journal of Cardiology
Verified
Journal Article
Closed access
SRSaul A. Rios
Saul A. Rios
CBClaudio Bravo
Claudio Bravo
MWMichael Weinreich
Michael Weinreich
WOWilman Olmedo
Wilman Olmedo
PVPedro Villablanca
Pedro Villablanca
UJUlrich P. Jorde
Ulrich P. Jorde

Verified
Journal Article
Open access
PDF file
CBCecilia Berardi
Cecilia Berardi
CBClaudio Bravo
Claudio Bravo
SLSong Li
Song Li
MKMaziar Khorsandi
Maziar Khorsandi
JKJeffrey E. Keenan
Jeffrey E. Keenan
CMClaudius Mahr
Claudius Mahr
The utilization of left ventricular assist devices (LVADs) in end-stage heart failure has doubled in the past ten years and is bound to continue to increase. Since the first of these devices was approved in 1994, the technology has changed tremendously, and so has the medical and surgical management of these patients. In this review, we discuss the history of LVADs, evaluating survival and complications over time. We also aim to discuss practical aspects of the medical and surgical management of LVAD patients and future directions for outcome improvement in this population.

3 May 2017 in Cochrane Database of Systematic Reviews
Verified
Journal Article
Closed access
PDF file
CBClaudio Bravo
Claudio Bravo
SHSameer A Hirji
Sameer A Hirji
DBDeepak L Bhatt
Deepak L Bhatt
RKRachna Kataria
Rachna Kataria
DFDavid P Faxon
David P Faxon
JBJames M Brennan
James M Brennan

20 June 2021 in Journal of Cardiac Failure
Verified
Journal Article
Closed access
CBClaudio Bravo
Claudio Bravo
JFJustin A. Fried
Justin A. Fried
JWJoshua Z. Willey
Joshua Z. Willey
AJAzka Javaid
Azka Javaid
GMGiulio M. Mondellini
Giulio M. Mondellini
PCPaolo C. Colombo
Paolo C. Colombo

1 November 2024 in Circulation: Heart Failure
Verified
Journal Article
Closed access
HPHongyang Pi
Hongyang Pi
LXLu Xia
Lu Xia
OBOlivier Boucherat
Olivier Boucherat
KSKarthik Suresh
Karthik Suresh
AHAnna R. Hemnes
Anna R. Hemnes
PLPeter J. Leary
Peter J. Leary
BACKGROUND: Pulmonary arterial hypertension (PAH) is a disease of progressive right ventricular (RV) failure with high morbidity and mortality. Our goal is to investigate proteomic features and pathways associated with RV-focused outcomes including mortality, RV dilation, and NT-proBNP (N-terminal pro-B-type natriuretic peptide) in PAH. METHODS: Participants in a single-institution cohort with 3 years of follow-up underwent proteomic profiling of their plasma using 7288 aptamers (targeting 6467 unique human proteins). Partial least squares discriminant analysis was performed to assess global protein variation associated with mortality, RV dilation, and NT-proBNP levels. Differentially abundant proteins and enriched pathways associated with outcomes were identified following baseline adjustments. RV vulnerability models estimated associations for individuals with similar afterload following adjustment for pulmonary vascular resistance. RESULTS: A total of 117 participants with PAH were included. Partial least squares discriminant analysis of the proteome showed clear separation between survivors and nonsurvivors, participants with dilated versus nondilated RVs, and across NT-proBNP levels. Proteins and pathways involving the ECM (extracellular matrix) were upregulated in participants who died during follow-up, those with severe RV dilation, and those with higher levels of NT-proBNP. Pulmonary vascular resistance adjustment reinforced the importance of ECM proteins in the association with RV vulnerability, independent of afterload. These findings were confirmed in independent PAH cohorts with available plasma proteomics and RV tissue gene and protein expression. CONCLUSIONS: Distinct plasma proteomic profiles are associated with mortality, RV dilation, and NT-proBNP in PAH. Proteins and pathways governing tissue remodeling are strongly associated with poor outcomes, may mediate RV vulnerability to right heart failure, and represent promising candidates as biomarkers and potential therapeutic targets.